Table 1. Baseline characteristics by type of second-line antidiabetic medication.
| Variable | MET+SU (n=4,447) | MET+DPP4i (n=6,136) | MET+TZD (n=617) | P value |
|---|---|---|---|---|
| Age, yr | 61.1±10.6 | 58.1±10.5 | 58.1±10.5 | <0.001 |
| Men, sex | 2,064 (46.4) | 2,927 (47.7) | 323 (52.4) | 0.018 |
| Duration of MET monotherapy, mo | 10.1±3.5 | 10.3±3.6 | 10.2±3.6 | 0.002 |
| Duration of second line therapy, mo | 20.3±17.2 | 19.7±15.7 | 18.6±16.5 | <0.001 |
| Comorbidities | ||||
| Hypertension | 3,166 (71.2) | 4,124 (67.2) | 410 (66.5) | <0.001 |
| Dyslipidemia | 3,155 (71.0) | 5,029 (82.0) | 482 (78.1) | <0.001 |
| Atrial fibrillation | 67 (1.5) | 108 (1.8) | 10 (1.6) | 0.599 |
| Chronic kidney disease | 59 (1.3) | 65 (1.1) | 6 (1.0) | 0.405 |
| Diabetic neuropathy | 652 (14.7) | 877 (14.3) | 69 (11.2) | 0.068 |
| Diabetic nephropathy | 328 (7.4) | 662 (10.8) | 72 (11.7) | <0.001 |
| Charlson score, unit | 3.3±1.8 | 3.2±1.7 | 3.2±1.7 | 0.072 |
| Intravitreal injection | 46 (1.0) | 60 (1.0) | 3 (0.5) | 0.429 |
| Inclusion year | <0.001 | |||
| 2009 | 2,120 (47.7) | 3,079 (50.2) | 355 (57.5) | |
| 2010 | 1,113 (25.0) | 1,547 (25.2) | 128 (20.8) | |
| 2011 | 685 (15.4) | 899 (14.7) | 84 (13.6) | |
| 2012 | 529 (11.9) | 611 (10.0) | 50 (8.1) |
Values are presented as mean±standard deviation or number (%).
MET, metformin; SU, sulfonylurea; DPP4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione.